Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20).
about
HIV-1 entry inhibitors: an overviewHIV-1 entry inhibitors: recent development and clinical useA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroMicrobicides and other topical agents in the prevention of HIV and sexually transmitted infections.Closing the door to human immunodeficiency virus.Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity.Novel compounds for the treatment of HIV type-1 infection.Immunotherapeutic restoration in HIV-infected individuals.HIV-1 Entry, Inhibitors, and ResistanceProtein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection.Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients.CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.New mechanism for release of endosomal contents: osmotic lysis via nigericin-mediated K+/H+ exchange.Anti-retroviral drugs: current state and development in the next decade.
P2860
Q24645525-7DCDA1F5-F9E9-41AE-86E3-353E74620D17Q27003887-D2226C4E-37E9-46DC-B834-B689CDB32D41Q28728917-A5A5BEC2-329D-4D72-9CDF-A9BE95BC7018Q30359545-8B32F9A6-F6DC-4F2C-9AAB-654DEF449CCBQ30428089-75535FC3-5C5B-4A85-8959-200336111DB1Q33810849-B1F128C3-D632-4C8C-B216-5E309D634672Q37302902-933AC2F5-67EC-496E-8D85-C503672FE3AFQ37502492-733580AC-E7EA-46DD-A48F-B7444504BC83Q37842335-B615E99A-074A-455D-8B6C-823B850A3EF5Q37945205-7B1BA3CA-51D2-42AD-819A-2A4A0FA4A896Q38574172-8BC5D912-1E2B-4F7D-99B1-6A1875D45DBBQ39238361-B1DC0BF3-2F7F-4B42-9FE4-96BDAE1ABF7BQ39330860-A026AF6D-81E3-4C6C-8CE5-FDDBED016E84Q39518073-B0B31748-CCB4-4CA8-A588-78F9F1D36171Q41762652-A9FE4B39-01A3-456B-8F02-90264ABC0E8CQ45959890-F625E0B8-C51B-4EED-9835-02377182C9B0Q47174470-55F9681E-1FDD-4BF4-8C00-FA68478E0D8DQ49987235-4CCBB57F-E40A-475B-BC80-B1A67003796FQ54222874-4BE518F2-0C3F-45B9-B07C-37E1EB2576EB
P2860
Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20).
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Synergistic in vitro antiretro ...... X-355) and enfuvirtide (T-20).
@ast
Synergistic in vitro antiretro ...... X-355) and enfuvirtide (T-20).
@en
Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody
@nl
type
label
Synergistic in vitro antiretro ...... X-355) and enfuvirtide (T-20).
@ast
Synergistic in vitro antiretro ...... X-355) and enfuvirtide (T-20).
@en
Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody
@nl
prefLabel
Synergistic in vitro antiretro ...... X-355) and enfuvirtide (T-20).
@ast
Synergistic in vitro antiretro ...... X-355) and enfuvirtide (T-20).
@en
Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody
@nl
P2093
P2860
P356
P1476
Synergistic in vitro antiretro ...... X-355) and enfuvirtide (T-20).
@en
P2093
Meredith Sorensen
Michael Fung
Robert T Schooley
Xing-Quan Zhang
P2860
P304
P356
10.1128/AAC.00761-05
P407
P577
2006-06-01T00:00:00Z